VistaGen Therapeutics, Inc. (VSTA) Gives Second Life to Once-promising Drug Candidates
Biotechnology company VistaGen Therapeutics is putting humans first with Human Clinical Trials in a Test Tube. This human pluripotent stem cell (hPSC) technology platform has been developed to provide clinically relevant predictions of potential toxicity long before drug candidates are ever tested on humans. VistaGen’s hPSC-based bioassay systems simulate human biology much more effectively than animal testing and other nonclinical techniques and technologies currently used in drug development. This superior approximation of human physiology enables pharmaceutical companies to better predict potential pitfalls in promising drug candidates during preclinical development – potentially saving millions of dollars and countless hours. Many times,…